Mirum Pharmaceuticals Quarterly Balance Sheet
NASDAQ: MIRMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Mirum Pharmaceuticals financial position
As of Jun 30, 2026, Mirum Pharmaceuticals reported total assets of $1.04 billion, up 44.0% from a year earlier against total liabilities of $1.06 billion. Shareholders' equity was negative at -$10.4 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $330.7 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 2.86, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Mirum Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 330.73M | 324.91M | 296.68M | 282.02M | 228.12M | 211.82M | 222.50M | 222.97M | 233.25M | 302.84M | 286.33M | 303.06M |
| Short-Term Investments | 107.56M | 61.35M | 86.64M | 93.53M | 76.43M | 65.85M | 57.81M | 61.48M | 45.13M | — | 0 | 2.97M |
| Receivables | 145.36M | 133.11M | 123.33M | 107.13M | 106.84M | 95.85M | 78.29M | 68.53M | 60.43M | 55.00M | 67.97M | 47.83M |
| Inventory | 25.77M | 25.52M | 24.89M | 24.02M | 22.94M | 22.42M | 22.40M | 21.59M | 20.44M | 21.61M | 22.31M | 22.25M |
| Total Current Assets | 636.31M | 569.44M | 549.68M | 530.58M | 453.40M | 410.82M | 392.79M | 386.63M | 367.83M | 389.46M | 387.54M | 388.58M |
| Property, Plant & Equipment | 2.25M | 2.41M | 1.86M | 1.28M | 1.18M | 1.11M | 1.14M | 1.21M | 1.10M | 501.00K | 706.00K | 787.00K |
| Intangible Assets | 247.39M | 254.15M | 260.92M | 231.90M | 237.87M | 243.84M | 249.82M | 255.79M | 261.77M | 257.44M | 252.93M | 258.34M |
| Long-Term Investments | 123.03M | 34.35M | 8.11M | 2.47M | 17.11M | 20.91M | 12.53M | 9.32M | 17.07M | — | 0 | — |
| Total Assets | 1.04B | 890.92M | 842.81M | 785.12M | 725.83M | 690.25M | 670.75M | 667.89M | 660.75M | 651.96M | 646.62M | 650.64M |
| Accounts Payable | 23.43M | 59.40M | 9.61M | 12.17M | 17.66M | 11.64M | 14.62M | 9.54M | 9.84M | 15.98M | 7.42M | 7.37M |
| Total Current Liabilities | 222.79M | 272.82M | 205.80M | 160.36M | 144.80M | 127.58M | 126.55M | 115.75M | 112.31M | 105.91M | 87.06M | 74.66M |
| Total Liabilities | 1.06B | 648.42M | 528.12M | 493.07M | 470.67M | 456.99M | 445.11M | 435.87M | 431.77M | 417.36M | 397.95M | 381.56M |
| Shareholders' Equity | -10.42M | 242.49M | 314.69M | 292.05M | 255.16M | 233.26M | 225.64M | 232.02M | 228.99M | 234.60M | 248.67M | 269.08M |
| Retained Earnings | -1.52B | -1.46B | -667.54M | -661.81M | -664.72M | -658.86M | -644.18M | -620.39M | -606.16M | -581.52M | -556.24M | -520.58M |
| Net Cash (Debt) | 438.29M | 386.26M | 383.33M | 375.55M | 304.55M | 277.67M | 280.31M | 284.44M | 278.37M | 302.84M | 286.33M | 306.03M |
| Shares Outstanding | 64.75M | 60.93M | 51.90M | 51.31M | 50.06M | 49.45M | 48.34M | 47.97M | 47.57M | 47.06M | 46.72M | 46.60M |
This table shows 12 quarterly periods of Mirum Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 16 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow MIRM's reporting calendar. What is a balance sheet?